Multimodal Imaging Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Multimodal Imaging Market Trends and Insights

Growing Prevalence of Chronic Diseases

Rising incidence of cancer and cardiovascular disorders keeps demand for sophisticated diagnostics high. Multimodal imaging delivers metabolic–anatomical correlation that single-modality exams cannot match, positioning the modality at the centre of preventive-care strategies. Cardiovascular MRI contributed measurable cost savings and outcome gains in a 361-patient study, underscoring health-economic value. Utilisation is projected to climb 27% in 30 years, reflecting demographic ageing and expanding clinical protocols rather than population growth alone. Oncology PET/CT volumes will benefit directly, as metabolic mapping improves early tumour detection and response assessment. The sustained rise in non-communicable disease prevalence therefore injects durable momentum into the multimodal imaging market.

Technological Advancements in Hybrid Modalities

Hybrid scanners now integrate AI to automate protocols and sharpen image clarity. Siemens Healthineers’ Biograph Horizon employs 4 × 4 mm LSO crystals and true time-of-flight, delivering high-resolution studies at reduced dose. Total-body PET enables dynamic acquisition, producing superior contrast while shrinking acquisition windows. Philips and NVIDIA jointly built MR foundation models that allow “zero-click” planning, promoting reproducibility and faster throughput. Such advances reduce technologist workload, increase scanner utilisation, and strengthen clinical-decision support—elements that fuel uptake across the multimodal imaging market.

Rising Demand for Early Cancer Diagnosis

Screening programmes now embed multimodal workflows to heighten accuracy. The FDA cleared Lumisight and Lumicell DVS fluorescence guidance for breast-conserving surgery, achieving 84% accuracy in detecting residual disease and cutting re-operation risk. PET/MRI in cervical cancer, augmented by parallel-encoder U-Net, reached a 0.726 Dice score for tumour segmentation. 18F-FES PET combined with 18F-FDG elevates confidence when staging estrogen-receptor-positive breast tumours. These breakthroughs reinforce the pre-eminence of hybrid modalities in oncology and expand the addressable base for the multimodal imaging market.

Increasing PET/CT Use in Cardiology Workflows

Cardiac PET/CT distinguishes viable from scarred myocardium, guiding revascularisation and raising quality-adjusted life years at acceptable thresholds. Long-axial field-of-view PET/CT reduces radiation while enabling faster whole-body studies, beneficial for unstable cardiac patients. AI-driven quantification packages accelerate perfusion analysis and standardise reporting. Together, these factors integrate cardiac PET/CT deeper into routine cardiology pathways, broadening revenue streams for the multimodal imaging market. Integration with AI-powered analysis platforms streamlines workflow efficiency while maintaining diagnostic accuracy standards required for clinical decision-making.

High Capital and Maintenance Costs

Hybrid scanners require multi-million-dollar outlays and specialised upkeep, hampering acquisition in budget-constrained settings. Emergency-department studies show that although multimodal CT elevates diagnostic certainty for dizziness, economic burden deters blanket implementation.^{[1]Source: Long H. Tu, “Cost-Effectiveness of CT, CTA, MRI…,” PUBMED.NCBI.NLM.NIH.GOV} Reimbursement frameworks often trail innovation, amplifying payback risk and limiting diffusion across the multimodal imaging market. The diagnostic imaging market faces consolidation pressures as providers seek economies of scale to manage these cost challenges while maintaining service quality standards.

Inadequate Imaging Infrastructure (Emerging Markets)

Power-supply variability, cooling requirements, and limited engineering workforces restrict hybrid technology roll-outs in developing economies. Regulatory diversity further complicates approvals, with decentralised EU pathways contrasting US FDA reviews.^{[2]Source: Long H. Tu, “Cost-Effectiveness of CT, CTA, MRI…,” PUBMED.NCBI.NLM.NIH.GOV} Training gaps intensify deployment challenges, slowing growth in the multimodal imaging market across underserved geographies. These infrastructure gaps particularly affect rural and underserved populations where portable solutions offer the most significant potential impact.

Segment Analysis

By Technology: Hybrid PET/CT Remains Mainstay While PET/MR Accelerates

PET/CT systems accounted for 61.86% of the multimodal imaging market share in 2024, supported by broad clinical guidelines and mature reimbursement pathways. This technology underpins cancer staging, myocardial perfusion, and neurological metabolism evaluation, making it indispensable for hospital workflows. The multimodal imaging market size for PET/CT is growing closely with expanding oncology caseloads. Vendors differentiate via detector materials, longer axial field-of-view, and AI-assisted protocol optimisation to shrink radiation dose and speed throughput.  

PET/MR, though currently smaller, records a 6.16% CAGR, buoyed by unparalleled soft-tissue contrast and reduced ionising exposure. Advances in deep-learning reconstruction, such as Philips SmartSpeed Precise, now cut exam times and improve SNR, making PET/MR more workflow-friendly. The multimodal imaging market size for PET/MR is projected to grow in the coming years as oncology centres adopt the modality for paediatric and neuro-oncology indications. SPECT/CT sustains demand in bone metastasis and cardiology perfusion, where isotope costs remain manageable. Niche combinations, including ultrasound/CT, hold specialised roles in interventional suites, rounding out the technology mix within the multimodal imaging market.

Note: Segment shares of all individual segments available upon report purchase

By Application: Oncology Dominates, Cardiology and Neurology Gain Momentum

Oncology controlled 59.12% of the multimodal imaging market size in 2024, and a forward CAGR of 5.9%. Tumour-specific radiotracers, fluorescence-guided resection, and AI-driven segmentation expand clinical utility, reinforcing the value proposition of hybrid platforms. Cardiology follows, leveraging PET/CT to quantify perfusion and plaque inflammation, an approach forecast to capture a growth of 7.69% in the coming years from 2025 to 2030. 

Neurology applications, from amyloid‐beta imaging to epilepsy focus localisation, register steady uptake as ageing populations boost dementia screening. Musculoskeletal applications demonstrate strong growth potential through PET/CT and PET/MRI capabilities in detecting bone metastases and inflammatory conditions, with nuclear medicine applications showing particular promise in MSK infection diagnosis. Ophthalmology and musculoskeletal segments, though smaller, employ multimodal retinal imaging and PET/MRI for inflammatory joint disease, respectively, illustrating diverse demand pockets that enrich the multimodal imaging market. 

By End-User: Hospitals Anchor Demand While Imaging-Centre Networks Scale

Hospitals captured 72.16% of the multimodal imaging market share in 2024 thanks to integrated oncology and cardiology service lines that rely on in-house hybrid scanners for procedural planning and follow-up. The multimodal imaging market size within hospitals is expected to grow in the coming years as tertiary centres upgrade to total-body PET. These centers leverage focused expertise and streamlined operations to deliver cost-effective imaging services while maintaining quality standards comparable to hospital-based facilities.

Diagnostic imaging centres post a 6.39% CAGR, propelled by outpatient shift and payer preference for cost-efficient venues. Franchise models that deploy portable PET/CT and helium-free MRI broaden geographic reach, increasing scanner utilisation. Research institutions and ambulatory surgery centres contribute niche demand driven by clinical trials and intra-operative guidance, respectively, further diversifying the multimodal imaging market.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America’s multimodal imaging market size reached USD 1.76 billion in 2024, equivalent to 40.16% global share, reflecting comprehensive insurance coverage and rapid AI workflow integration. Concentrated expertise at academic medical centres accelerates technology diffusion, while cross-border collaborations enhance Canadian capacity. Mexico’s private hospitals seize market openings generated by medical tourism, adding incremental demand for hybrid scanners.  

Asia-Pacific posts the highest CAGR at 6.84%. China funds large-scale oncology and cardiology programmes that mandate PET/CT inclusion, whereas Japan upgrades ageing scanners to maintain diagnostic excellence for an elderly population. India’s private networks install digital PET/CT and 1.5T helium-free MRI in tier-1 cities, widening access. Australia and South Korea adopt cutting-edge platforms comparable to Western peers, reinforcing regional momentum.

Europe maintains a mature yet expanding base, with Germany spearheading innovation through local manufacturing and R&D. Unified valuation frameworks under the European Health Technology Assessment Regulation streamline procurement, underpinning continued adoption. Southern European nations deploy EU-funded tele-imaging initiatives that link rural clinics to urban centres, integrating portable PET/CT to extend reach. Collectively these dynamics keep Europe’s multimodal imaging market on a stable growth.